Initial Therapeutics is an ATP company that develops small-molecule medicines designed to prevent pathogenic protein synthesis. The company provides an approach that is differentiated from protein degradation and other interventions that recognize and tackle proteins only after they are fully formed for medical needs.

Initial Therapeutics

Initial Therapeutics' headquarters in New York, NY, United States

Director, Discovery Science

Brooke Olson Blair

Fred Ward

Julius K.

The Scientific Research Team at Initial Therapeutics is responsible for conducting advanced research to identify and develop small-molecule medicines aimed at preventing pathogenic protein synthesis. This involves employing a range of scientific techniques, including computational biology, to discover and validate targets, as well as to optimize drug candidates for therapeutic use.

Scientific Research Team

This department provides expert advice and strategies to clients across various domains.

Consulting Services

This department focuses on scientific research and the development of innovative solutions.

Initial Therapeutics

Org chart

Teams

Scientific Research Team

Consulting Services

Research and Development

Offices

Initial Therapeutics

Org chart

Teams

Scientific Research Team

Consulting Services

Research and Development

Offices

Related companies